Guardant Health, Inc. (GH)
| Market Cap | 24.07B +237.5% |
| Revenue (ttm) | 1.18B +42.7% |
| Net Income | -453.44M |
| EPS | -3.50 |
| Shares Out | 134.20M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,080,734 |
| Open | 183.00 |
| Previous Close | 183.10 |
| Day's Range | 175.62 - 183.50 |
| 52-Week Range | 55.38 - 183.51 |
| Beta | 1.58 |
| Analysts | Strong Buy |
| Price Target | 195.81 (+9.16%) |
| Earnings Date | Oct 28, 2026 |
About GH
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal test, a blood test that utilizes circulating tumor DNA to detect cancer at the molecular level; and Guardant360 Tissue test, a molecular profiling test for tumor tissue that provides genomic, transc... [Read more]
Financial Performance
In 2025, Guardant Health's revenue was $982.02 million, an increase of 32.88% compared to the previous year's $739.02 million. Losses were -$416.28 million, -4.61% less than in 2024.
Financial StatementsAnalyst Summary
According to 26 analysts, the average rating for GH stock is "Strong Buy." The 12-month stock price target is $195.81, which is an increase of 9.16% from the latest price.
News
Guardant Health Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Q2 saw strong revenue and volume growth, with Shield now covering 80% of eligible patients and significant cost reductions underway. Guardant360 and Reveal platforms are expanding clinical use cases, while commercial wins and product innovation position the company for continued growth.
Guardant Health's Shield Blood Test Covered by EviCore by Evernorth for Colorectal Cancer Screening
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield™ blood test for colorectal cancer screening (CRC) will be cover...
Guardant Health and Collaborators to Present 20 Abstracts Highlighting Portfolio of Liquid Biopsy Tests for Early Detection and Ongoing Treatment Management at 2026 World Conference on Lung Cancer
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the company and its research collaborators will present 20 abstracts—...
Guardant Health assumed with a Buy at UBS
UBS assumed coverage of Guardant Health (GH) with a Buy rating and $225 price target Guardant Health is a core diagnostics holding, driven by durable growth across G360 liquid and…
Business Insider Names Guardant Health One of America's Most Innovative Businesses
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it has been named to Business Insider's America's Most Innovative Business...
Guardant Health initiated with a Buy at Rothschild & Co Redburn
Rothschild & Co Redburn initiated coverage of Guardant Health (GH) with a Buy rating and $203 price target The firm says Guardant is the leader in testing via liquid biopsy.
Guardant announces FDA approval of Guardant360 CDx as companion diagnostic
Guardant Health (GH) announced that the U.S. Food and Drug Administration has approved Guardant360 CDx as a companion diagnostic to identify patients with hormone receptor-positive, HER2-negative adva...
Guardant Health Announces Landmark FDA Approval of Guardant360® CDx as Companion Diagnostic for AstraZeneca's ETCAMAH™ (camizestrant) in Advanced Breast Cancer
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved Guardant360®...
Guardant Health management to meet with Piper Sandler
Meeting to be held on September 10-11 hosted by Piper Sandler.
Elevance update guidelines cover Freenome CRC test, says Guggenheim
Guggenheim noted that Elevance Health’s (ELV) Carelon Healthcare Services unit updated its clinical guidelines for average-risk colorectal cancer screening to cover Guardant Health’s (GH) Shield and t...
Guardant Health’s Shield Blood test covered by Carelon Health Services
Guardant Health (GH) announced its Shield blood test for colorectal cancer screening will be covered in Carelon Healthcare Services clinical guidelines effective November 15. Carelon Healthcare Servic...
Guardant Health's Shield Blood Test Covered by Carelon Health Services for Colorectal Cancer Screening
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield™ blood test for colorectal cancer screening (CRC) will be cover...
Guardant Health to appeal federal district court judgment in TwinStrand case
Guardant Health (GH) announced it will appeal the final judgment from the U.S. District Court for the District of Delaware related to intellectual property claims brought against Guardant by TwinStran...
Guardant Health to Appeal Federal District Court Judgment
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will appeal the final judgment from the U.S. District Court for the Dis...
U.S. court orders Guardant to pay $245 million in DNA sequencing patent dispute
A U.S. court has ordered Guardant Health to pay more than $245.2 million to TwinStrand Biosciences and the University of Washington after finding that the company infringed patents covering DNA sequ...
Guardant Health Transcript: Canaccord Genuity's 46th Annual Growth Conference
Strong Q2 2026 results featured rapid growth in core oncology diagnostics, with Shield and Reveal products driving significant volume and revenue gains. Major payer coverage, cost reductions, and expanding clinical indications position the portfolio for continued momentum and broader market impact.
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on July 21, 2026, the Compensation Committee of Guardant's Board of D...
Guardant Health price target raised to $185 from $175 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Guardant Health (GH) to $185 from $175 and keeps an Overweight rating on the shares.
Guardant Health price target raised to $195 from $170 at Stephens
Stephens raised the firm’s price target on Guardant Health (GH) to $195 from $170 and keeps an Overweight rating on the shares. Guardant reported “strong” Q2 results and second half…
Guardant Health price target raised to $193 from $135 at Piper Sandler
Piper Sandler raised the firm’s price target on Guardant Health (GH) to $193 from $135 following quarterly results. The firm keeps an Overweight rating on the shares. Published first on…
Guardant Health price target raised to $180 from $130 at Stifel
Stifel analyst Daniel Arias raised the firm’s price target on Guardant Health (GH) to $180 from $130 and keeps a Buy rating on the shares after “another clean beat and…
Biotech company launches multi-cancer detection test
Guardant Health co-founder and co-CEO Helmy Eltoukhy discusses his company's blood test for colorectal cancer on ‘The Claman Countdown.'
Guardant Health price target raised to $200 from $185 at RBC Capital
RBC Capital analyst Dan Leonard raised the firm’s price target on Guardant Health (GH) to $200 from $185 and keeps an Outperform rating on the shares. The firm cites the…
Guardant Health price target raised to $210 from $200 at TD Cowen
TD Cowen raised the firm’s price target on Guardant Health (GH) to $210 from $200 and keeps a Buy rating on the shares. The firm said expectations were high for…
Guardant Health price target raised to $195 from $190 at BTIG
BTIG raised the firm’s price target on Guardant Health (GH) to $195 from $190 and keeps a Buy rating on the shares. The company drove another strong beat and raise…